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Abstract
Background: Previous population-based studies have demonstrated an association between metformin use and
improved survival among diabetic patients with cancer. We sought to analyze the effects of diabetes and its
treatment in terms of the survival of patients with lung cancer.
Methods: Overall, 1106 patients with non-small cell lung cancer (94.3 % with stage IV disease) were included. The
outcomes were compared between the patients with (n = 186) and without diabetes (n = 920). The characteristics
associated with antidiabetic treatment and proper glycemic control (defined as a mean plasma glucose <130 mg/dL)
were examined at diagnosis. The overall survivals (OSs) of the different patient populations were analyzed using
Kaplan-Meier curves, and a multivariate Cox proportional hazard model was used to determine the influences of the
patient and tumor characteristics on survival.
Results: The OS for the entire population was 18.3 months (95 % CI 16.1-20.4). There was no difference in the OSs of
the diabetic and non-diabetic patients (18.5 vs 16.4 months, p = 0.62). The diabetic patients taking metformin exhibited
a superior OS than did those on other antidiabetic treatments (25.6 vs 13.2 months, p = 0.017). Those with proper
glycemic control had a better OS than did those without proper glycemic control and the non-diabetics (40.5 vs 13.2
and 18.5 months, respectively, p < 0.001). Both the use of metformin (HR 0.53, p < 0.0001 and HR 0.57, p = 0.017,
respectively) and proper glycemic control (HR 0.49, p < 0.0001 and HR 0.40, p = 0.002, respectively) were significant
protective factors in all and only diabetic patients, respectively.
Conclusions: The diabetic patients with proper glycemic control exhibited a better OS than did those without proper
glycemic control and even exhibited a better OS than did the patients without diabetes mellitus. Metformin use was
independently associated with a better OS.
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Background
In Mexico, more than 95 % of all patients with non-
small cell lung cancer (NSCLC) present with advanced-
stage disease at the time of diagnosis [1]. Because the
prevalence of type 2 diabetes is high both worldwide and
in Mexico, it is very important to understand the effects
of preexisting diabetes on the survival of patients with
advanced NSCLC. The physiopathology of diabetes, the
effects of its treatment and the changes in different
organ systems observed in diabetic patients might be as-
sociated with clinical outcomes. Existing data regarding
the effects of diabetes on NSCLC outcomes are conflict-
ing. Although some early studies found longer survival
rates in diabetic patients with NSCLC [2], this result was
not confirmed in other larger series [3, 4]. Indeed, an el-
evated fasting glucose level was found to be independ-
ently associated with a significantly higher risk of
mortality in patients with NSCLC [3].
Among the major hypoglycemic agents that are used
for the treatment of diabetes, metformin has received
the most attention regarding its potential antineoplastic
uses. At the cellular level, metformin has profound ef-
fects on the mitochondrial respiration rate and the pro-
duction of ATP [5]. Metformin affects multiple cellular
pathways via the activation of AMP-activated protein
kinase (AMPK) by liver kinase 1 (LKB1), which leads to
decreases in growth factor signaling and proliferation via
the inhibition of mTOR [6].
There is a general lack of information regarding the
outcomes of diabetic patients with NSCLC who are
treated with different antidiabetic agents, including met-
formin, and the published data come from large epi-
demiological databases that are prone to bias [7]. In this
study, our objective was to analyze the effects of diabetes
and its treatment in terms of the survival of patients
with NSCLC.
Methods
We conducted a retrospective cohort observational
study. Consecutive patients diagnosed with NSCLC at
the Instituto Nacional de Cancerología (INCan) between
January 2008 and December 2014 were retrieved from
our electronic medical records. The study was approved
by INCan’s research committee (REV/05/16). Because
the study was deemed as without risk, patient consent
was not required. The patient and tumor characteristics,
including age, comorbidities, body mass index, stage at
diagnosis, tobacco use, wood smoke exposure and muta-
tional analysis results, were obtained. All patients were
staged using thoracic and abdominal CT scans, PET
scans and MRI imaging of the central nervous system.
Previous diagnoses of diabetes, current antidiabetic
treatments and glucose measurements for each individ-
ual patient were also recorded at the time of the lung
cancer diagnosis. The patients were considered to have a
diagnosis of diabetes if they either fulfilled the American
Diabetes Association (ADA) criteria for diabetes or were
being treated with antidiabetic medications prior to
diagnosis with NSCLC. The patients were treated ac-
cording to published guidelines for the treatment of lung
cancer [8]. Patients with missing data were excluded
from the analysis.
Proper glycemic control was defined by a pre-prandial
(fasting) glucose level of 70–130 mg/dL at the time of
the lung cancer diagnosis, in accordance with the
current guidelines of the ADA [9]. Because most pa-
tients lacked a measurement of glycated hemoglobin
(HbA1C), we calculated the mean plasma glucose by
averaging the patient’s pre-prandial glucose measure-
ments (at least 3). We considered patients with mean
plasma glucose levels under 130 mg/dL to be within the
proper glycemic control goals and those with a mean
plasma glucose level over 130 mg/dL to have improperly
controlled diabetes. The overall survival (OS) was calcu-
lated from the date of cancer diagnosis to the date of the
last visit or death.
The de-identified patient dataset supporting the con-
clusions of this article is included within the article and
its additional supporting file (Additional file 1).
Statistical analysis
For descriptive purposes, the continuous variables are
summarized as arithmetic means with standard devia-
tions (SD) and as medians with ranges. The categorical
variables are summarized as the relative frequencies,
proportions, and 95 % confidence intervals (95 % CI).
The Pearson chi-square test was used to compare the
data between the diabetic and non-diabetic patients and
between the patients with and without proper glycemic
control. The OSs were analyzed using the Kaplan-Meier
method, and comparisons between subgroups were per-
formed using the log-rank test or the Breslow test. Sta-
tistically significant and borderline significant variables
(p < 0.1) were included in a multivariate analysis. The
Cox proportional hazards model was used to estimate
the hazard ratios (HRs) and 95 % CI. The variables that
were included in the multivariate analysis were factors
that are known to be associated with poor outcomes for
patients with NSCLC (i.e., age, ECOG performance sta-
tus, tumor stage, smoking status, epidermal growth fac-
tor receptor (EGFR) mutational status and metastatic
disease). The variables of interest in the study (i.e., diag-
nosis of diabetes, mean plasma glucose and antidiabetic
medications) and the variables that were found to be sig-
nificant in the univariate analysis at the level of p < 0.01
were also included in the model. The SPSS software
package (version 22.0; SPSS, Chicago, IL, USA) was used
for the data analysis. All p values presented are two-
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A total of 1106 patients with diagnoses of NSCLC were
identified and considered eligible for the analysis. The
median age was 61 years (SD ± 13 years). Most of the pa-
tients were male (53 %) and had a history of smoking
(58.8 %). ECOG PSs of 0-1 were observed in 75 % of the
patients, 68.2 % of the patients had adenocarcinoma
histologic diagnosis, and 94.3 % were stage IV (M1a and
M1b). Only 417 patients (37.7 %) had undergone EGFR
mutation testing, and 152 (36.5 %) of these patients were
positive.
Diabetes was present in 186 (16.8 %) of the patients at
the time of cancer diagnosis. The characteristics of the
diabetic and non-diabetic patients are presented and
compared in Table 1. The calculated mean serum glu-
cose was higher in the patients with diabetes than in the
non-diabetics (170 mg/dL [±78.5 mg/dL] vs 105 mg/dL
[±14.5 mg/dL], p < 0.0001). There were no differences in
stage, performance status, mutational status, smoking
history or gender between the diabetic and non-diabetic
patients. Metformin was used as an antidiabetic treat-
ment at the time of diagnosis by 59.7 % of the diabetic
patients, and 31.4 % were within the predefined defin-
ition of proper glycemic control (Table 2). Eighty-one
percent (n = 150) of the diabetic patients had completed
at least one line of treatment with either chemotherapy
or tyrosine kinase inhibitors.
Factors associated with survival in the overall cohort
The median follow-up time was 10.8 months (0.6-111.1),
and the median OS for the entire cohort was 18.3 months
[95 % CI 16.1-20.4]. The factors associated with OS are
presented in Table 3. Female gender (p < 0.0001), no his-
tory of smoking (p < 0.01) and a lower stage at diagnosis
(p < 0.0001) were associated with improved survival.
Compared with the non-diabetic population, the pa-
tients with diabetes mellitus had a similar OS (18.5 vs.
16.4 months p = 0.619, Fig. 1a). However, the patients
with proper glycemic control exhibited a better OS
(40.5 months [95 % CI 11.2–69.8]) than did the diabetic
patients without proper glycemic control (13.2 months
[95 % CI 12–14.4]) and even exhibited a better OS than
did the patients without diabetes mellitus (18.5 months
[95 % CI 16.2–20.7]; Fig. 1b). Metformin use was associ-
ated with an improved OS in all of the patients, includ-
ing the patients with and without diabetes mellitus
(25.6 months [95 % CI 13.7–37.6] vs 18.3 months [95 %
CI 15.9–20.6], p = 0.046; Fig. 1c). The factors that were
independently associated with improved survival in the
complete cohort are presented in Table 4.
Factors associated with survival in the diabetic patients
The univariate analyses revealed that the factors associ-
ated with improved OS in the diabetic patients were
lower stage at diagnosis, the use of metformin and
proper glycemic control (Table 3). Compared with the
diabetic patients who were using other antidiabetic med-
ications, the patients taking metformin exhibited a sig-
nificantly better OS (25.6 [95 % CI 13.7–37.6] vs
13.2 months [95 % CI 11.9–14.5]; p = 0.017, Fig. 1d). The
largest improvement in OS was observed in the diabetic
patients who achieved proper glycemic control (as de-
fined by the calculated mean serum glucose; 40.5 vs
13.2 months; p <0.001). The diabetic patients with
proper glycemic control exhibited a better OS than did
Table 1 Comparison of baseline characteristics between






% (n/N) % (n/N)
Gender 0.44
Female 47.2 (434/920) 46.2 (86/186)
Male 52.8 (486/920) 53.8 (100/186)
Age at diagnosis (mean) <0.0001
Mean (SD) 51.2 (13.1) 64.5 (10.5)
Smoking history 0.22
Non-smoker 40.7 (374/920) 44.1 (82/186)
Smoker 59.3 (546/920) 55.9 (104/186)
Histology 0.48
Adenocarcinoma 68.3 (628/920) 67.7 (126/186)
Other 31.7 (292/920) 32.3 (60/186)
Disease Stage 0.36
II-IIIa 5.5 (51/920) 6.5 (12/186)
IIIb-IV 94.5 (869/920) 93.5 (174/186)
ECOG PS 0.31
0–1 74.5(685/920) 78 (145/186)
2–4 25.5 (235/920) 22 (41/186)
CNS metastases at diagnosis 0.09
Absent 53.5 (492/920) 47.8 (89/186)
Present 46.5 (428/920) 52.2 (97/186)
Basal Glucose <0.0001
Mean (SD) 105 (14.5) 170 (78.5)
EGFR mutation (n = 417) 0.09
Positive 34.9 (123/352) 44.6 (29/65)
Negative 65.1 (229/352) 55.4 (36/65)
KRAS mutation (n = 184) 0.60
Positive 16.3. (25/30) 16.7 (5/31)
Negative 83.7 (128/153) 83.9 (26/31)
ECOG PS Eastern Cooperative Oncology Group Performance Status Score
Arrieta et al. BMC Cancer  (2016) 16:633 Page 3 of 9
both the poorly controlled diabetic patients and the
non-diabetics (Fig. 1b). The multivariate analysis re-
vealed that both the use of metformin (HR 0.57 [95 % CI
0.36–0.90]; p = 0.017) and proper glycemic control (HR
0.40 [0.22–071]; p = 0.002) remained significant protect-
ive factors in the diabetic patient population (Table 4).
Discussion
Our results revealed that both the use of metformin and
the maintenance of proper glycemic control are related
to improved survival in the diabetic patients with ad-
vanced NSCLC. In our population, the use of metformin
and the maintenance of proper glycemic control affected
survival, independent of stage, histology and other anti-
diabetic treatments. Our results suggest that treatment
with metformin, but not other hypoglycemic agents, is
associated with a significant improvement in survival in
patients with NSCLC and diabetes.
Evidence from epidemiological studies and meta-
analyses has demonstrated associations of diabetes with
several malignancies, including pancreatic [10], breast
[11], prostate [12], colonic [13] and hepatocellular
carcinomas [14]. In contrast, the relationship between
diabetes and NSCLC is not well established, and epi-
demiological data have yielded conflicting results. Al-
though some studies have reported an association
between diabetes and NSCLC [15, 16], the majority has
reported null or inverse relationships [17–19]. This po-
tentially negative relationship is further illustrated by the
fact that NSCLC has not been found to be associated
with obesity, which is strongly related to the presence of
diabetes [20]. Indeed, a high body mass index has been
found to be a protective factor against NSCLC in some
studies [21]. Further, a recently published meta-analysis
by Zhang et al. concluded that metformin use in pa-
tients with diabetes appears to be associated with a re-
duced risk of lung cancer. This area requires further
study and should be considered in the treatment of pa-
tients with diabetes and NSCLC [22].
The association between diabetes mellitus and survival
in lung cancer patients is controversial [23] Whereas
some studies suggest that patients with diabetes mellitus
have worse prognoses due to comorbidities and disease
complications that can be related to a reduced tolerance
of treatment [24, 25], other studies have demonstrated
that diabetic patients exhibited increased survival com-
pared with non-diabetics [7, 26, 27]. The contradictory
results between different studies might be the conse-
quence of the analyses of heterogeneous populations. In
the present study, we found that diabetes mellitus was
not associated with an improved OS in all patients; how-
ever, our findings demonstrated that the diabetic pa-
tients with proper glycemic control exhibited a better
OS than did the other diabetic patients and even the
non-diabetics, which is consistent with previously pub-
lished data [26].
Metformin has been explored as a pharmacological
agent that may improve the survival of patients with sev-
eral types of cancer. A recent meta-analysis reported as-
sociations between metformin and prolonged survival in
patients with breast, colorectal, ovarian and endometrial
cancers [28]. In NSCLC patients, the benefit of metfor-
min on the prognosis has been demonstrated in large
epidemiological studies [11] and in a meta-analysis [29].
Unfortunately, the main limitation of these studies is
that they included heterogeneous patients and treat-
ments and were thus prone to bias. In contrast, our re-
port included a large set of NSCLC patients who were
treated at a single reference institution where the preva-
lence of diabetes is high.
One potential explanation for the beneficial effects of
metformin and proper glycemic control is that both are
related to a reduction in circulating insulin levels. Insu-
lin can stimulate both the insulin receptor (IR) and the
insulin-like growth factor-1 receptor (IGF-1R), and both
of these receptors are overexpressed in NSCLC patients
and correlated with worse prognoses [30] and poor re-
sponses to targeted treatments [31]. Metformin has been
demonstrated to interact with IGF signaling to reduce
both the proliferation and migration of cancer cells [29].
There is a growing body of evidence regarding the
Table 2 Treatment and glycemic control in the diabetic patient
population (N = 186)














Mean (± S.D.) 170 (78.5)
Range 74–604
Glycemic Control (n = 185)a
Proper (<130 mg/dLb) 31.2 (58/185)
Improper (≥130 mg/dLb) 68.8 (127/185)
a One patient with missing glucose values
b Calculated mean serum glucose
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Table 3 Overall survival and patient characteristics of the entire patient population (n= 1106) and the diabetic patient population (n = 186)
Entire Patient Population (n = 1106) Diabetic Patient Population (n = 186)
Characteristic OS (m)
n
95 % CI p OS (m)
n
































































































Glycemic control <0.001 <0.0001
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Table 3 Overall survival and patient characteristics of the entire patient population (n= 1106) and the diabetic patient population (n = 186)
(Continued)
Glycemic control and diabetesb <0.001
Proper diabetic control 40.5
58
11.2–69.8






OS Overall Survival, m Months
a Calculated mean serum glucose b One patient with missing glucose values
Fig. 1 Overall survival comparisons of the patients. a Overall Survival comparison between diabetic and non-diabetic patients; b Overall Survival
comparison between diabetic patients with and without proper glycemic control, and non-diabetic patients; c Overall Survival comparison between
diabetic patients with and without use of metformin; d Overall Survival comparison between diabetic patients using metformin or using other
antidiabetic treatment
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effects of metformin on the multiple pathways that regu-
late carcinogenesis. Metformin inhibits mTOR transla-
tion initiation, the epithelial-mesenchymal transition
(EMT), IL-6 secretion and STAT3 activity [32]. Thus,
several preclinical experiments have tested combinations
of metformin with radiotherapy [33], chemotherapy [34]
and targeted therapies in lung cancer patients to over-
come the mechanisms of resistance and to achieve syn-
ergy [35]. Metformin has been demonstrated to sensitize
EGFR tyrosine kinase inhibitor (TKI)-resistant lung can-
cer cells by reversing the EMT and decreasing IL-6 sig-
naling activation [32]. The combination of gefitinib (a
reversible EGFR-TKI) and metformin induces a strong
antiproliferative effect in NSCLC cell lines that harbor
the wild-type LKB-1 gene [36]. Antiproliferative syner-
gism between metformin and the multikinase inhibitor
sorafenib via AMPK activation has also been demon-
strated in NSCLC cells that harbor KRAS mutations
[37]. Taken together, these data have led to the design of
clinical trials utilizing combinations of metformin and
targeted therapies for NSCLC patients who harbor spe-
cific mutations [38]. The ALMERA trial is an ongoing
phase II trial conducted by the Ontario Clinical Oncol-
ogy Group that will provide prospective evidence regard-
ing the potential of metformin to improve the outcomes
of standard cytotoxic therapy in locally advanced
NSCLC patients [39].
Due to its retrospective nature, our study has some in-
herent limitations. HbA1c measurements were not avail-
able for the majority of the patients; therefore, we were
unable to clearly identify patients with proper glycemic
control. To resolve this issue, we calculated the mean
plasma glucose levels using the fasting measurements
from each patient. Although it was not ideal, this ap-
proach yielded the expected results in terms of the com-
parisons of the patient groups. Additionally, due to the
retrospective nature of the data, we were unable to as-
sess whether the patients who were not taking metfor-
min had specific contraindications for its use or whether
the patients with metformin prescriptions properly ad-
hered to their treatment regimen. Furthermore, we had
no data regarding whether patients who failed to achieve
proper glycemic control were undergoing different types
of treatment (e.g., chemotherapy rather than targeted
therapy) that might have included high-dose steroids or
had negative effects on proper adherence.
It is important to mention that our patients exhibited
particularly prolonged average OS despite having advanced
stage NSCLC. This finding may have resulted from the
large incidence of EGFR-mutated tumors in our popula-
tion [40, 41] and the broad access to clinical trials available
at our institution. Some retrospective studies have associ-
ated the use of metformin with a lower risk of lung cancer,
but the designs of these studies have been questioned due
to time-related bias [42, 43]. To reduce the risk of this
bias, both metformin use and proper glycemic control
were assessed at the time of the lung cancer diagnoses.
It is possible that patients undergoing cytotoxic
chemotherapy rather than targeted therapy would be
more likely to stop taking metformin or that the drug
could have different effects depending on the mutational
statuses of the patients. However, the small number of
EGFR and KRAS patients taking metformin made it dif-
ficult to draw any conclusions regarding these particu-
larly interesting populations.
Finally, we were unable to gather data about the re-
lated metabolic comorbidities, such as waist circumfer-
ence and lipid levels. However, given that mortality in
this patient population is mostly cancer-related, we be-
lieve that the influences of such comorbidities on out-
come would be minimal.
Conclusion
The diabetic patients with proper glycemic control exhib-
ited better OS than the diabetic patients without proper
glycemic control and even exhibited better OS than did
the patients without diabetes mellitus. Metformin use was
independently associated with improved OS.
The use of metformin and the achievement of proper
glycemic control have beneficial effects on the survival
of patients with diabetes and advanced NSCLC. Prospect-
ive clinical trials of the use of metformin for lung cancer
should be performed, particularly in selected populations
in which the effects of metformin on signaling pathways
could be potentially beneficial.
Table 4 Multivariate analysis of factors predicting survival in the
entire patient population and in the diabetic patient population
Variable All patients
HR 95 % CI P
Gender 1.39 1.13–1.72 0.002
Smoking History 1.18 0.95–1.44 0.132
Histology 0.92 0.75–1.12 0.421
Clinical Stage IIIB-IV 2.03 1.33–3.08 0.001
ECOG Performance Status 1.26 1.10–1.43 0.001
Metformin use 0.53 0.37–0.75 <0.0001
Glycemic control 0.49 0.39–0.63 <0.0001
Diabetic patient population
HR 95 % CI P
Gender 1.36 0.80–2.33 0.256
Smoking History 1.35 0.79–2.31 0.277
Clinical Stage IIIB-IV 3.01 0.92–9.84 0.068
Metformin use 0.57 0.36–0.90 0.017
Proper glycemic control 0.40 0.22–0.71 0.002
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